Saturday 17 October 2026 Export PRTCY’s income statement to Excel — free account

PureTech Health PLC Sponsored ADR

PureTech Health PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $4.7 million, down 3.50% from fiscal 2024.

14.56 0.34 −2.28%

Follow PRTCY

Alert me

Market cap: $424.0M
P/E: 0.0×
Fwd P/E: −3.7×
Dividend yield: —
F-score: 4/9
Altman Z: 0.83
Beneish M: 1.48
Dividend safety: n/a

Overview Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 94.46%

Capital & Financial Ratios $m

Market Cap 424.00

Revenue 30.04

Net Income (175.97)

Free Cash Flow (344.59)

Net Debt (288.72)

Current Ratio 6.59

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (3.68)

P/S ratio 0.00

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth (40.65%)

Next Y EPS Growth (7.11%)

Next Y revenue growth 72.08%

Next 5Y EPS Growth (28.77%)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

EV/FCF against its own 10 years 66.26%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2022	2023	2024	2025
Cash	350	327	379	289
Receivables	22	14	2	8
Inventory	—	—	—	—
Other	2	2	2	2
	386	347	386	305

	2022	2023	2024	2025
Payables	55	44	27	23
ST’ Debt	5	—	—	—
Other	27	0	7	13
	97	51	41	46

Compound Annual Growth %

	10y	5y	3y
Sales	(0.51%)	(16.92%)	(33.18%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	3.60%	(14.10%)	(17.66%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	—	—	—	—	5
’24	—	—	—	—	5
’23	—	—	—	—	3
’22	—	—	—	—	16
’21	—	—	—	—	17
’20	—	—	—	—	12

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	—	—	—	—	(85)
’24	—	—	—	—	(134)
’23	—	—	—	—	(106)
’22	—	—	—	—	(179)
’21	—	—	—	—	(158)
’20	—	—	—	—	(132)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	—	(46)	—	(85)	(85)
’24	—	(80)	—	(134)	(134)
’23	—	(65)	—	(105)	(105)
’22	—	(89)	—	(181)	(181)
’22	—	—	—	—	(196)
’21	—	(65)	—	(164)	(164)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	—	—	—	—	(4.57)
’24	—	—	—	—	0.21
’23	—	—	—	—	(2.41)
’22	—	—	—	—	(0.18)
’21	—	—	—	—	(2.19)
’20	—	—	—	—	0.02

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	33.00	35.00	18.15	17.08	18.19	13.30	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	56.89	65.90	43.57	38.49	34.00	20.00
People
People	Employees	—	—	—	300	300	250	111	96	80	62
	Revenue/emp, $m	0.00	0.00	0.00	0.03	0.04	0.07	0.14	0.03	0.06	0.08
Income, $m
Income, $m	Revenue	5	2	21	10	12	17	16	3	5	5
	Gross margin, %	0.00	0.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00
	EBT	(92)	(51)	(68)	478	19	(59)	(93)	(36)	24	(111)
	EBT margin, %	(1,877.29)	(2,094.83)	(329.85)	4,878.90	161.19	(339.04)	(594.08)	(1,084.17)	492.42	(2,380.92)
	Net income	(54)	0	(71)	366	5	(63)	(37)	(67)	28	(110)
	Depreciation	2	2	3	7	7	7	9	5	4	3
Per share, $
Per share, $	Revenue	0.02	0.01	0.08	0.03	0.04	0.61	0.55	0.12	0.19	0.19
	Earnings	(0.24)	0.11	(0.26)	1.29	0.02	(2.11)	(0.18)	(2.41)	0.21	(4.57)
	Cash flow	(0.28)	(0.36)	(0.27)	(0.35)	(0.46)	(5.52)	(6.28)	(3.83)	(5.28)	(3.54)
	Capex	0.00	0.00	(0.02)	(0.04)	(0.02)	(0.20)	(0.08)	0.02	0.01	0.01
	Free cash flow	(0.28)	(0.36)	(0.28)	(0.39)	(0.48)	(5.72)	(6.36)	(3.81)	(5.27)	(3.52)
	Book value	0.94	0.81	0.00	2.29	2.29	20.38	19.23	16.58	16.03	12.69
	Shares, m	230	236	274	283	286	29	28	28	25	24
Valuation, ×
Valuation, ×	P/E	20.92	20.92	20.92	20.92	35.29	0.00	0.00	0.00	0.00	0.00
	P/S	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/B	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	EV/Sales	(5.96)	(5.96)	(5.96)	(5.96)	(10.99)	(15.97)	(10.25)	(10.38)	(12.10)	(9.10)
	EV/FCF	0.74	0.74	0.74	0.74	0.75	1.06	0.66	0.71	0.95	0.79
Cash, $m
Cash, $m	Operating cash flow	(64)	(85)	(73)	(98)	(132)	(158)	(179)	(106)	(134)	(85)
	Capex	(4)	(2)	(4)	(13)	(5)	(6)	(2)	1	0	0
	Free cash flow	(64)	(85)	(77)	(111)	(137)	(164)	(181)	(105)	(134)	(85)
Balance, $m
Balance, $m	Working capital	102	(69)	(6)	30	233	276	289	296	345	259
	Total debt	125	116	244	136	15	15	15	—	—	—
	Net debt	(216)	(57)	(25)	(162)	(389)	(466)	(335)	(327)	(379)	(289)
	Shareholders’ equity	215	192	292	650	654	584	548	458	408	306
Returns, %
Returns, %	ROA	(16.09)	0.00	(18.63)	59.74	0.62	(6.26)	(6.11)	(9.54)	8.25	(19.30)
	ROIC	0.00	0.00	0.00	(17.34)	(28.25)	(79.30)	(58.07)	(69.70)	(290.85)	(363.08)
	ROE	(26.58)	12.50	0.00	89.35	0.92	(9.79)	(8.90)	(13.25)	12.36	(30.76)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
PROK ProKidney Corp.	$439.9M	— (loss-making)	— (loss-making)	−32.13% (below 0%: shrinking)	n/m	−28.03% (below 0%: shrinking)	100.00%	(32,248.67%)	Compare
INDP Indaptus Therapeutics, Inc.	$437.7M	— (loss-making)	—	—	n/m	+52.03% (above 0%: growing)	0.00%	0.00%	Compare
PRTA Prothena Corporation plc	$436.4M	— (loss-making)	188×	−77.15% (below 0%: shrinking)	n/m	+44.64% (above 0%: growing)	100.00%	(2,089.21%)	Compare
DMAC DiaMedica Therapeutics, Inc.	$433.6M	— (loss-making)	— (loss-making)	—	n/m	−6.75% (below 0%: shrinking)	0.00%	0.00%	Compare
PRTCY PureTech Health PLC Sponsored ADR	$424.0M	— (loss-making)	— (loss-making)	−44.60% (below 0%: shrinking)	+66.43% (above 0%: growing)	+19.27% (above 0%: growing)	2.83%	0.00%
CAPR Capricor Therapeutics, Inc.	$422.7M	— (loss-making)	— (loss-making)	−7.92% (below 0%: shrinking)	n/m	−72.88% (below 0%: shrinking)	100.00%	0.00%	Compare
ASMB Assembly Biosciences, Inc.	$418.8M	19.7×	— (loss-making)	+38.94% (above 0%: growing)	n/m	+7.58% (above 0%: growing)	100.00%	(47.44%)	Compare
TECX Tectonic Therapeutic, Inc.	$416.4M	— (loss-making)	—	—	n/m	−46.69% (below 0%: shrinking)	0.00%	0.00%	Compare
ZURA Zura Bio Limited	$410.2M	— (loss-making)	—	—	n/m	−30.41% (below 0%: shrinking)	—	0.00%	Compare
Median of peers	$428.1M	—	—	−20.02%	—	−17.39%	100.00%	0.00%

All 614 Biotechnology stocks →

PureTech Health PLC Sponsored ADR (PRTCY) key facts

Concern: PureTech Health PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $4.7 million, down 3.50% from fiscal 2024.
PureTech Health PLC Sponsored ADR (PRTCY) is a Biotechnology company in the Healthcare sector.
As of October 15, 2026, PRTCY traded at $14.56, a market capitalization of $424.0 million.
Return on equity was −30.8% and debt-to-equity 0.00.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is 0.83 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.